GHRH analogs and GHRPs studied for adult-onset GH deficiency — ranked by clinical evidence, mechanism fidelity, and axis-preservation profile.
Adult growth hormone deficiency (GHD) is characterized by reduced pulsatile GH secretion from the anterior pituitary, leading to increased visceral adiposity, reduced lean mass, decreased bone mineral density, fatigue, and impaired quality of life. Research peptides in the GHRH analog and GHRP classes offer a mechanism-based approach to restoring GH axis function — either by stimulating the pituitary directly (GHRH analogs) or by amplifying GH pulse magnitude via ghrelin receptors (GHRPs).
The key distinction between these peptides and exogenous HGH is axis preservation: GHRH analogs work through the pituitary's own regulatory machinery, maintaining somatostatin feedback and physiological GH pulsatility. This makes them a fundamentally different — and in many research contexts, preferable — approach to GH axis support.
Research Disclaimer: All content on this page is for educational and research purposes only. These compounds are not FDA-approved for human use except where noted (Tesamorelin/Egrifta). Always consult a qualified healthcare professional before considering any peptide protocol.
Sermorelin and Tesamorelin bind pituitary GHRH receptors to stimulate endogenous GH synthesis and pulsatile release. Axis-preserving — works with natural somatostatin feedback.
Ipamorelin acts on ghrelin receptors to amplify GH pulse magnitude. Selective for GH release with minimal cortisol or prolactin elevation. Synergistic with GHRH analogs.
CJC-1295 with DAC binds serum albumin to extend half-life to 6–8 days, producing sustained GH elevation. Trades pulsatility for convenience and sustained IGF-1 support.
GHRH(1-29)NH₂ — axis-preserving GH stimulation with natural pulsatile release
Sermorelin is a synthetic analog of endogenous GHRH comprising the biologically active N-terminal 29 amino acids. It binds pituitary GHRH receptors to stimulate GH synthesis and secretion in natural pulses, preserving somatostatin feedback and avoiding supraphysiological GH levels. Its short half-life (~10–20 minutes) mirrors the physiological GHRH burst, making it the most axis-faithful GHRH analog available.
Multiple clinical trials demonstrating GH axis restoration, IGF-1 normalization, and body composition improvement. Axis-preserving mechanism confirmed in pituitary response studies.
Administer in a fasted state before bed when somatostatin tone is lowest. Monitor IGF-1 levels to assess response. Preferred over CJC-1295 when preserving natural pulsatility is the primary goal.
Full-length GHRH analog — FDA-approved for visceral fat reduction via GH axis
Tesamorelin is a synthetic analog of the full 44-amino-acid GHRH sequence, modified with a trans-3-hexenoic acid group to extend stability. It stimulates pulsatile GH secretion from the anterior pituitary, which acts on adipose tissue to reduce visceral fat and on muscle and bone to improve body composition. FDA-approved for HIV-associated lipodystrophy; extensively studied for metabolic GHD.
Phase 3 trials: significant visceral fat reduction vs placebo. FDA-approved (Egrifta). IGF-1 normalization confirmed. Studied in non-HIV metabolic syndrome.
Most clinically validated GHRH analog. Particularly effective for visceral adiposity. Higher cost than Sermorelin. Requires daily injection. Discontinuation leads to fat regain.
Long-acting GHRH analog — sustained GH elevation via DAC modification
CJC-1295 is a GHRH analog modified with a Drug Affinity Complex (DAC) that covalently binds to serum albumin, extending its half-life from minutes to 6–8 days. This produces sustained GH elevation rather than pulsatile release. Often combined with Ipamorelin (a GHRP) to amplify GH pulse magnitude while CJC-1295 provides the sustained baseline.
Phase 2 trials showing sustained IGF-1 elevation and GH release. Commonly used in research protocols for body composition and GH axis support.
The DAC modification produces a continuous GH elevation rather than physiological pulses. Some researchers prefer CJC-1295 without DAC (Mod GRF 1-29) for pulsatile release. Frequently stacked with Ipamorelin.
Selective GHRP — clean GH pulse amplification with minimal side effects
Ipamorelin is a selective growth hormone-releasing peptide (GHRP) that acts on ghrelin receptors in the pituitary and hypothalamus to amplify GH pulse magnitude. Unlike other GHRPs (GHRP-2, GHRP-6), Ipamorelin does not significantly elevate cortisol or prolactin, making it the cleanest GHRP available. Most commonly stacked with CJC-1295 or Sermorelin to achieve both GHRH and GHRP axis stimulation simultaneously.
Preclinical and early clinical data showing selective GH release without cortisol/prolactin elevation. Widely used in research stacks for GH axis support.
Best used in combination with a GHRH analog (Sermorelin or CJC-1295) rather than alone. The GHRH + GHRP combination produces synergistic GH pulse amplification. Minimal side effects compared to other GHRPs.
The most evidence-backed peptides for stimulating the GH axis are: Sermorelin (GHRH analog, 29-amino-acid fragment, restores pulsatile GH release), Tesamorelin (full-length GHRH analog, FDA-approved for HIV lipodystrophy), CJC-1295 (long-acting GHRH analog with DAC modification), and Ipamorelin (selective GHRP with minimal cortisol/prolactin elevation). Sermorelin is the most commonly researched for adult-onset GHD because it preserves the natural somatostatin feedback loop.
Sermorelin stimulates the pituitary to release its own GH in natural pulses, preserving somatostatin feedback and avoiding supraphysiological GH levels. Synthetic HGH (somatropin) bypasses the pituitary entirely and delivers exogenous GH directly, which can suppress natural GH production over time. Sermorelin is considered axis-preserving — it works with the body's regulatory system rather than replacing it.
Sermorelin is the biologically active N-terminal 29 amino acids of native GHRH with a short half-life (~10-20 minutes), producing physiological GH pulses. CJC-1295 is a modified GHRH analog with a DAC (Drug Affinity Complex) modification that extends its half-life to 6-8 days, producing sustained GH elevation rather than pulsatile release. Sermorelin is preferred when preserving natural pulsatility is the goal; CJC-1295 is used when sustained GH elevation is desired.
GHRH analogs like Sermorelin and Tesamorelin are not direct replacements for HGH therapy in cases of severe pituitary failure, where the pituitary cannot respond to GHRH stimulation. However, in cases of functional GHD (where the pituitary is intact but GH secretion is reduced), GHRH analogs can effectively restore GH pulsatility. A GHRH stimulation test can determine whether the pituitary is capable of responding.
Research protocols typically use 100–300 mcg of Sermorelin administered subcutaneously before bed (when natural GH pulsatility is highest and somatostatin tone is lowest). Cycles of 3–6 months are common, with IGF-1 levels used to monitor response. Sermorelin should be administered in a fasted state to avoid blunting the GH response by elevated insulin.
Adult GHD symptoms include increased visceral adiposity (particularly abdominal fat), reduced lean muscle mass, decreased bone mineral density, fatigue, impaired quality of life, dyslipidemia (elevated LDL, reduced HDL), and reduced exercise capacity. Sermorelin and Tesamorelin research has specifically targeted visceral fat reduction and body composition improvement in adults with functional GHD.
GHRH analogs preserve the natural somatostatin feedback loop, preventing the pituitary suppression associated with exogenous HGH. This makes them preferable for long-term GH axis support research.
IGF-1 levels are the primary biomarker for assessing GH axis response to GHRH analog protocols. Target range in research is typically 200–350 ng/mL (age-adjusted). Testing every 4–6 weeks during active protocols is standard practice.
GHRH analogs are most effective when administered before bed in a fasted state, when somatostatin tone is lowest and natural GH pulsatility is highest. Insulin elevation blunts the GH response — avoid carbohydrates 2–3 hours before administration.
Combining a GHRH analog (Sermorelin or CJC-1295) with a GHRP (Ipamorelin) produces synergistic GH pulse amplification — the GHRH analog sets the pulse timing while the GHRP amplifies pulse magnitude. This combination is the most common research stack for GH axis support.
Sermorelin, Tesamorelin, CJC-1295, and Ipamorelin — available at Purgo Labs with third-party COA verification and ≥99% purity.
Shop Purgo LabsUse code HEALTH for 15% off
Medical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.